CAPRISA Trial and 1% Tenofovir Gel in Reducing the Risk of Contracting HIV
Tenofovir gel could prevent new HIV infections in close to a half million women over the next decade in South Africa alone. The results from this trial are a significant first step toward establishing the effectiveness of antiretroviral drugs for HIV prevention; confirmatory studies are now urgently needed.